Invesco India Pharma and Healthcare Fund - Regular Plan - Growth
💡 Why Pick This Fund? Quantitative Strengths & Watch-outs
- Expense ratio (3.8%) is higher than category median (2.52%), which creates fee drag over time.
Key Statistics vs Category Median
Trailing Returns Comparison
| Period | Fund Return | Category Median | Difference |
|---|---|---|---|
| 1 Month | +12.18% | +6.32% | +5.86% |
Calendar Year Returns
| Year | Fund | Category Median | Gap |
|---|---|---|---|
| 2026 | +4.90% | +4.03% | +0.87% |
Risk Profile & Deepest Drawdowns
Deepest Market Corrections (Depth >= 10%)
| Peak Date | Trough Date | Fall Depth | Months to Bottom | Recovery Period |
|---|---|---|---|---|
| 2026-09-23 | 2026-10-23 | -11.5% | 1 months | 1 months |
Portfolio & Asset Allocation
Statutory Asset Allocation Mandate (SEBI / SID)
| Instrument Category | Permitted Allocation Range |
|---|---|
| Equity and Equity related instruments of companies in the Pharma, Healthcare and allied sectors : Min. 80% Max 100% ; Other equity and equity related instruments : Min. 0% Max 20% ; Money Market / Other Liquid Instruments : Min. 0% Max 20% ; Gold / Silver ETFs : Min. 0% Max. 20% ; Units issued by InvITs : Min. 0% Max 10% | Per Scheme Mandate |
Investment Objective & Strategy
To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.
ℹ️ Detailed monthly stock-level holdings for this scheme are updated periodically from asset management company statutory disclosures.
Fund Size Position
Currently managing Rs 526 cr (AMFI Daily Fund AUM as of 2026-11-11). Positioned as comfortable relative to Sectoral / Thematic schemes.
Fund Management
Cost & Capital Gains Taxation
From April 2026 the total expense ratio includes brokerage, transaction costs and statutory levies on top of the base fee.
Equity-oriented schemes: 20% short-term capital gains tax if sold within 12 months; 12.5% long-term capital gains tax on gains exceeding ₹1.25 lakh per financial year when held for more than 12 months.
Closest Sectoral / Thematic Peers by Rank
| Scheme | Score | 3Y Return | Expense | Downside | Fund Size | Compare |
|---|---|---|---|---|---|---|
| SBI HEALTHCARE OPPORTUNITIES FUND | 7.2 | +23.97% | 1.98% | 43.4% | Rs 6,504 cr | Compare → |
| UTI Healthcare Fund | 7.0 | +22.74% | 2.20% | 57.0% | Rs 1,536 cr | Compare → |
| Mirae Asset Healthcare Fund | 7.9 | +22.67% | - | 45.7% | Rs 3,828 cr | Compare → |
| Nippon India Taiwan Equity fund | 7.2 | +45.47% | 2.39% | -77.2% | Rs 806 cr | Compare → |
| DSP Healthcare Fund | 8.0 | +20.31% | 2.04% | 53.2% | Rs 3,946 cr | Compare → |
Frequently Asked Questions about Invesco India Pharma and Healthcare Fund
What is the expense ratio of Invesco India Pharma and Healthcare Fund?
Invesco India Pharma and Healthcare Fund has a total expense ratio (TER) of 3.8% with a base expense ratio of 2.09%, compared to the Sectoral / Thematic category median of 2.52%.
Who manages Invesco India Pharma and Healthcare Fund?
Invesco India Pharma and Healthcare Fund is managed by Aditya Khemani (tenure: 0.2 years since 2026-09-07).
What are the historical returns of Invesco India Pharma and Healthcare Fund?
Invesco India Pharma and Healthcare Fund has a 1-year return of -.
How large is Invesco India Pharma and Healthcare Fund?
Invesco India Pharma and Healthcare Fund manages assets of Rs 526 cr, placing it in the 'comfortable' size band relative to Sectoral / Thematic peers.
How is Invesco India Pharma and Healthcare Fund scored on MFIQ?
Invesco India Pharma and Healthcare Fund holds an MFIQ Score of 5.5/10 (Average), based on a category percentile composite across returns, risk, consistency, and cost.
How risky is Invesco India Pharma and Healthcare Fund?
Invesco India Pharma and Healthcare Fund has an official SEBI riskometer rating of Very High. Over the analyzed period, its annualized standard deviation is - with a maximum historical drawdown of -11.50%.